Variant Perception
Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.
Where We Disagree With the Market
The market is debating the wrong binary. Bull, Bear and sell-side coverage have all converged on the 1 October 2026 vape duty as the decisive variable, with the H1 FY27 print in November 2026 as the resolver — but the duty is fully calendared, the rate is set, and the 20 April 2026 trading update has already shown vape revenue can grow 10% through a $70m disposable runoff. The genuinely undated, undisclosed, single-RNS binary is whether Heaven Gifts (the Chinese parent of ElfBar / Lost Mary) repeats its US "build-a-beachhead-then-go-direct" playbook in the UK on roughly $97m of H1 FY26 vape revenue Supreme distributes but does not own. Two further disagreements compound this: the consensus reading of the 54.27% founder stake as alignment ignores that the same founder rewrote the long-term incentive plan in FY25 into a one-year Adjusted-EBITDA SIP that mechanically rewards each next acquisition; and the implicit segment values inside the 5.0x EV/EBITDA group multiple are inverted — Electricals (~30% UK battery share, exclusive Energizer/JCB licences) is the segment with the cleanest moat, Vaping (56% of revenue) is the segment with rented brand economics. None of these views require a contrarian narrative; they require the market to look at the disagreement ledger one row past the duty.
Variant Perception Scorecard
Variant strength (0-100)
Consensus clarity (0-100)
Evidence strength (0-100)
Months to first resolver
The variant strength score reflects three real but contained disagreements with the market — material enough to change underwriting, not radical enough to reposition the stock against a clear consensus tape. Consensus is unusually clear here: every public anchor (sell-side, the death cross, the 5.0x multiple, the 20 April trading update reaction) points to the same single binary, which is exactly what creates the asymmetry on the second binary nobody is sizing. Evidence strength sits in the mid-60s because the disintermediation thesis is supported by a documented Reuters playbook and the H1 FY26 deliberate diversification into IVG / Hayati, but the contract terms with Heaven Gifts are not public — so the disagreement is structural, not specific. The first hard resolver is the FY26 final results in early July (cash conversion, segment GM); the H1 FY27 print in late November 2026 is the cleanest test, roughly nine months out.
The single highest-conviction disagreement. The market is paying a duty-pass-through discount on the wrong binary. The Oct-2026 duty is well-known and the 20 April 2026 trading update has materially de-risked the disposable-substitution leg of the bear case. The undated, single-RNS Heaven Gifts disintermediation risk is sitting inside the same 5.0x EV/EBITDA — and it is the binary that would change segment economics most quickly if it lands.
Consensus Map
What the market appears to believe, with the signals that make each belief consensus rather than just one analyst's view.
The cleanest single anchor for "what consensus believes" is the post-20-April-trading-update tape: the FY26 print landed materially ahead (revenue $365m vs $337m consensus, EBITDA $55.9m vs $50.9m), and the multiple stayed at 5.0x EV/EBITDA. That tells you the market re-priced the disposable-ban leg of the discount but kept the duty discount intact — a precise read on what is and is not in the price.
The Disagreement Ledger
Three ranked disagreements, each tied to specific evidence that is in the report but not in the price.
Disagreement #1 — the wrong binary. Consensus would say the Oct-2026 duty is the central event because the rate is large ($3.00 per 10ml is roughly half the wholesale price of a refill bottle), the timing is fixed, and pod GM has already shown 200bps of pre-duty compression. We disagree because the duty is priced and dated — the 5.0x multiple already discounts it. What is not priced is the binary loss of the master-distributor relationship that supplies 30% of vape revenue. The market would have to concede that Vape segment EBITDA could halve in a single RNS, not slide gradually across two reporting periods. The cleanest disconfirming signal is a multi-year ElfBar / Lost Mary renewal RNS or, equivalently, Supreme's vape mix migrating decisively toward owned 88Vape and IVG / Hayati so that ElfBar / Lost Mary falls below 20% of vape revenue — both of which would close the variant view.
Disagreement #2 — founder alignment vs. revenue-buying contract. Consensus would say a founder with $140m at risk and a 163x stake-to-pay ratio is structurally aligned with minorities. We disagree because alignment is what the contract says, and the contract was rewritten in FY25 to a one-year Adjusted-EBITDA SIP — a metric that the next acquisition mechanically lifts and that bargain-purchase accounting feeds into. The FY25 underlying number (Adjusted PBT -2% YoY ex Typhoo bargain gain) and the FY25 FCF-after-acquisitions number (-$4.8m) are exactly what you would expect from a contract that pays for revenue rather than for per-share economics. The market would have to concede that the M&A engine is partly a compensation engine — and re-rate quality of earnings down accordingly. The disconfirming signal is a reinstated 3-year LTIP with a TSR component, or three consecutive halves of cash conversion above 90% with no acquisition added to the base.
Disagreement #3 — inverted segment values. Consensus would say Vaping is the multiple-supporting segment because it has the highest gross margin and dominates revenue mix. We disagree because the moat work shows the segment with the most defensible economic position is Electricals: ~30% UK battery share, multi-decade exclusive licence portfolio, and a value-channel distribution density (50,000 retail outlets) that no UK FMCG peer matches. Vaping has higher headline margin but lower defensibility — pod GM compressed pre-duty, ~30% of revenue is rented from Heaven Gifts, and IMB blu carries the brand equity Supreme's 88Vape does not. The market would have to concede that any segment-multiple rerating story is anchored on the wrong segment, which makes the bull case dependent on Drinks & Wellness margin convergence rather than on vape pod GM. The disconfirming signal is Electricals revenue continuing to decline at -6%/year (the trend) without licence-renewal news — at which point the moat assertion fails on volume even if it holds on share.
Evidence That Changes the Odds
The eight pieces of evidence on this page that move the probability of the variant view, isolated from the headline narrative.
The eight items above are the evidence base for the variant view. None of them is exclusive to this analysis — every line is in an upstream tab. What changes when you read them as a set is which binary deserves the highest weight: the duty (consensus), the disintermediation (variant #1), the contract structure (variant #2), or the segment-mix inversion (variant #3).
How This Gets Resolved
The signals that close the disagreement, with the document or tape where each one will appear.
The resolution path is dense for a six-month window. Two binaries (vape duty pass-through and ElfBar disintermediation) have observable single-RNS resolvers; two structural views (contract-structure / quality-of-earnings, and segment-mix inversion) resolve gradually across the FY26 final, AGM and FY27 H1 prints. The sequence to watch is: FY26 finals (early July) → AGM remuneration vote and any bolt-on RNS (Aug-Sep) → 1 October 2026 duty effective → 25 November 2026 H1 FY27 print.
What Would Make Us Wrong
The strongest argument against variant view #1 — that the market has under-priced Heaven Gifts disintermediation — is that Supreme's H1 FY26 deliberate diversification into IVG and Hayati already shows management hedging the exact risk we are flagging. If the company is replacing the rented brand portfolio with new third-party brands at comparable wholesale margin and similar consumer pull, the binary loss event becomes a slow share rotation across reporting periods, not a single-RNS shock. In that scenario, our disagreement collapses into the consensus duty debate, and the 5.0x multiple is correctly priced because the binary we identified does not exist as a binary. The cleanest test is whether IVG and Hayati combined revenue can replace ElfBar / Lost Mary at sub-1.5x wholesale margin compression — which the FY26 final segment disclosure (early July) will give an early read on.
The strongest argument against variant view #2 — that founder alignment is being mis-read because the contract structure rewards revenue-buying — is the absolute size of the founder's stake. $140m at risk against $421k of base salary is alignment of an order most public companies do not have, and the dollar value of the bonus distortion (a few hundred thousand dollars per year) is trivial relative to the per-share value at risk in any equity raise or governance failure. If Sandy Chadha continues to hold above 50% and refuses to dilute through any acquisition between now and FY28, the contract structure is a second-order issue and the alignment narrative survives. The disconfirming signal here is straightforward: any further insider sale above the $4.1m November 2025 print, or a placing to fund a deal, would close the variant view in our favour; absence of either over the next 12 months would close it against us.
The strongest argument against variant view #3 — that segment values are inverted — is that Electricals' moat is being earned at a -6%/year revenue decline, and a moat on shrinking volume is a compromise asset, not a defensible one. A high-multiple rerating thesis genuinely should anchor on the largest revenue pool (Vaping) because that is where the dollar EBITDA sits. The segment-inversion view depends on Electricals stabilising, which it has not yet done; if FY27 prints another mid-single-digit Electricals decline, the market is correct to discount it as a melting cash floor and our segment-value attribution view is wrong on volume even if it is right on share-of-channel.
The honest red-team summary is that all three variant views are about risk weighting, not about thesis direction. We agree with the bull case that Supreme is high-quality, capital-efficient and trades at a discount that the operating evidence does not justify. We disagree on which binaries the discount is paying for — and on whether the founder-alignment narrative survives a careful read of the FY25 incentive change. None of these views imply that the stock is mispriced in the sense of "buy more"; they imply that the resolution map a PM actually monitors should be wider than the duty.
The first thing to watch is the H1 FY27 vape segment commentary in late November 2026 — not for the gross-margin number consensus is already focused on, but for the disclosed brand-mix breakdown that will tell you whether ElfBar / Lost Mary has been deliberately rotated below 20% of vape revenue. That single disclosure resolves variant view #1 in either direction more cleanly than any duty pass-through datapoint.